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Objective: Non-alcoholic fatty liver disease is a world-wide health concern and risk factor for cardio-metabolic diseases. Citrate uptake modiﬁes
intracellular hepatic energy metabolism and is controlled by the conserved sodium-dicarboxylate cotransporter solute carrier family 13 member 5
(SLC13A5, mammalian homolog of INDY: mINDY). In Drosophila melanogaster and Caenorhabditis elegans INDY reduction decreased whole-body
lipid accumulation. Genetic deletion of Slc13a5 in mice protected from diet-induced adiposity and insulin resistance. We hypothesized that
inducible hepatic mINDY inhibition should prevent the development of fatty liver and hepatic insulin resistance.
Methods: Adult C57BL/6J mice were fed a Western diet (60% kcal from fat, 21% kcal from carbohydrate) ad libitum. Knockdown of mINDY was
induced by weekly injection of a chemically modiﬁed, liver-selective siRNA for 8 weeks. Mice were metabolically characterized and the effect of
mINDY suppression on glucose tolerance as well as insulin sensitivity was assessed with an ipGTT and a hyperinsulinemic-euglycemic clamp.
Hepatic lipid accumulation was determined by biochemical measurements and histochemistry.
Results: Within the 8 week intervention, hepatic mINDY expression was suppressed by a liver-selective siRNA by over 60%. mINDY knockdown
improved hepatic insulin sensitivity (i.e. insulin-induced suppression of endogenous glucose production) of C57BL/6J mice in the
hyperinsulinemic-euglycemic clamp. Moreover, the siRNA-mediated mINDY inhibition prevented neutral lipid storage and triglyceride accumu-
lation in the liver, while we found no effect on body weight.
Conclusions: We show that inducible mINDY inhibition improved hepatic insulin sensitivity and prevented diet-induced non-alcoholic fatty liver
disease in adult C57BL6/J mice. These effects did not depend on changes of body weight or body composition.
 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Non-alcoholic fatty liver disease (NAFLD) is a global health concern.
Estimates suggest approximately 3.4 million deaths/year from obesity-
associated diseases such as cardiovascular disease, type-2 diabetes
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in up to 30% of Americans and is involved in the development of insulin
resistance (IR) and T2D [5]. Available treatment options for NAFLD are
sparse.
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insufﬁcient fatty acid (FA) oxidation and secretion from liver [7]. Hepatic
fat accumulation has been linked to IR via speciﬁc lipid species such as
diacylglycerols and ceramides [8].
Cytosolic citrate is a precursor for FA synthesis in the liver, and
consequently triacylglycerols and cholesterol. Moreover, citrate has
signaling properties modifying the activity of FA synthesis pathways by
an allosteric activation of acetyl-CoA carboxylase 2 [9]. The resulting
malonyl-CoA from this reaction inhibits FA oxidation. Moreover, citrate
has been shown to reduce the ﬂux of glucose through glycolysis in
human cells [10]. In liver and adipose tissue, the rate of FA synthesis
appears to correlate with the cytosolic citrate concentration and this is
partially depending on direct transport of citrate into the cell by solute
carrier family 13, member 5 (SLC13A5) [10].
The SLC13A5 gene is the mammalian ortholog of the ‘I’m not dead,
Yet’ (INDY) gene in Drosophila melanogaster where its mutation is
linked to a life-span extension [11]. The human SLC13A5 gene en-
codes a transmembrane sodium-dependent dicarboxylate cotrans-
porter protein [12]. In vertebrates, it is referred to as mammalian INDY
homolog (mINDY), Nact, or NaC2/NaCT. mINDY is highly expressed in
liver and moderately in brain, testis, and kidney, where it transports
TCA cycle intermediates, including succinate and citrate, but also
malate, fumarate and 2-oxo-glutarate [12e16]. The transport pro-
cess for cellular uptake of citrate is several times more selective than
for other TCA cycle intermediates [17]. The Naþ-dicarboxylate
cotransport process is electrogenic, coupling three to four Naþ ions to
the transport of each divalent anion substrate [12,17e19]. In D.
melanogaster and Caenorhabditis elegans, down-regulation of INDY
facilitated longevity similar to caloric restriction and resulted in
reduced fat storage in ﬂies [11,20,21]. We have recently shown in
C. elegans that longevity induced by INDY knockdown depends on
AMPK [22]. Genetic whole-body deletion of mINDY in mice also led to
striking similarities to caloric restriction and protected mice from
high-fat diet (HFD)-induced obesity, steatosis hepatis, and IR by
increasing energy expenditure, improving hepatic mitochondrial
biogenesis, enhancing hepatic FA oxidation, and reducing hepatic
lipogenesis [16]. In primary rat hepatocytes, mINDY expression and
citrate uptake could be induced by physiological concentrations of
glucagon via a cAMP-dependent and cAMP-responsive element-
binding protein (CREB)-dependent mechanism at a conﬁrmed CREB-
binding site within the mINDY promoter [23]. In line with these ob-
servations, the siRNA-mediated knockdown of mINDY in human
HepG2 cells reduced their lipid content [24].
Based on the predominant expression in liver, its relative selectivity for
citrate, and the promising data from existing studies including the
whole-body knockout (KO) experiments, mINDY is a potential thera-
peutic target to treat NAFLD and metabolic disorders in humans [14e
16,24].
We hypothesized that inducible hepatic mINDY inhibition should pre-
vent the development of fatty liver and hepatic IR. Therefore, we
investigated the effects of an inducible liver-speciﬁc, siRNA-based
mINDY knockdown in adult C57BL/6J mice.
2. MATERIAL AND METHODS
2.1. Materials
All chemicals were purchased from Sigma-Aldrich (Munich, Germany),
Merck (Darmstadt, Germany), or Roth (Karlsruhe, Germany), reagents
for RNA, cDNA, and qPCR were purchased from Thermo Scientiﬁc
(Schwerte, Germany), and radioactive labeled substances were pur-
chased from Hartman Analytic (Braunschweig, Germany) unless stated
otherwise.MOLECULAR METABOLISM 5 (2016) 1072e1082  2016TheAuthors. Published by ElsevierGmbH. This is an o
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All animal experiments were performed under the terms of the German
Animal Protection Law, and according to the EU Directive 2010/63/EU
for animal experiments as well as international animal welfare legis-
lation and rules. Additionally, mice studies were conducted according
to institutional ethical guidelines of the Charité Berlin, Germany, and
were approved by the Landesamt für Gesundheit und Soziales
(approval number G 0331/13, LAGeSo Berlin, Germany) and comply
with the ARRIVE guidelines [25].
8 week-old male C57BL6/J mice (Forschungseinrichtungen für
experimentelle Medizin, Charité Berlin, Germany) were fed ad libitum a
Western diet (WD) consisting of a HFD (60% kcal from fat, D12492 (I),
Ssniff Spezialdiäten, Soest, Germany; Supplemental Table A1) sup-
plemented with 6% sucrose in the water. All mice were maintained in
individually ventilated cages (4/cage) in an environmentally-controlled
room with a 12 h lightedark cycle. Body weight was monitored
weekly. For siRNA intervention mice were divided into two groups
according to equal fat mass. 1 mg/kg liver-selective mINDY-speciﬁc
(siINDY) or unspeciﬁc scrambled control siRNA (SCR) in PBS was
weekly injected via tail vein for 8 weeks. Body composition of mice was
assessed by 1H-magnetic resonance spectroscopy using a Minispec
LF50 Body Composition Analyzer (Bruker BioSpin, Billerica, USA).
Isoﬂurane inhalation (1.5%) was used for anesthesia during operation,
and mice were sacriﬁced by cervical dislocation.
2.2.1. Activity and calorimetry analysis
Basal metabolic parameters were analyzed in a TSE LabMaster System
(TSE Systems, Bad Homburg, Germany). Mice were acclimated to the
metabolic cages individually housed 16 h before starting and supplied
with WD. Data on gas exchanges, activity, and food/liquid intake was
collected for 48 h and analyzed as 24 h average. Calorimetry was
performed with a computer-controlled open circuit calorimetry system
composed of 10 metabolic cages. Each cage was equipped with a
special water bottle and a food tray connected to a balance as well as
an activity monitor. Parameters were measured for each mouse at
3 min intervals and respiratory quotient (RQ) was calculated as the
ratio of CO2 production to O2 consumption. O2 consumption, CO2
production, energy expenditure (EE), and caloric intake were adjusted
for lean body mass. Data were analyzed as described [26]. Additionally
taken in consideration that fat mass is metabolic active, there were no
differences in lean body or fat mass between siINDY and control
animals.
2.2.2. Glucose tolerance test (ipGTT)
Mice were fasted overnight and basal blood glucose was measured
before injecting an intraperitoneal glucose bolus of 1 g/kg body weight.
Blood glucose levels were measured subsequently at 0, 15, 30, 60 and
120 min and the corresponding insulin levels were determined.
2.2.3. Hyperinsulinemic-euglycemic clamp studies
Hyperinsulinemic-euglycemic (HE) clamp studies were performed in
conscious, restrained mice with 3 mU/kg/min insulin in a body weight
matched fashion and a 2-Deoxy-D-glucose (2-DG) bolus injection to
measure tissue-speciﬁc glucose uptake as described [16,27,28].
Indwelling jugular venous catheters were implanted, and mice
recovered for 7 days. Following an overnight fast, whole-body glucose
turnover was estimated under basal conditions with a 0.05 mCi/min
infusion of [2-3H]-D-glucose (HPLC puriﬁed) for 2 h. Afterwards, mice
were primed with human insulin (21.43 mU/kg, INSUMAN rapid;
Sanoﬁ-Aventis, Frankfurt, Deutschland) and [2-3H]-D-glucose
(0.72 mCi) over 3 min, followed by HE conditions for 140 min with apen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1073
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(0.1 mCi/min), and a variable infusion of 20% glucose to sustain
euglycemia around 120 mg/dl. At 85 min, a 10 mCi 2-Deoxy-D-[1-14C]-
glucose bolus was injected to assess insulin-stimulated tissue glucose
uptake. According to standard operating procedures [27,29], blood
sampling was done via tail. An albumin-containing solution mimicking
artiﬁcial plasma was infused (4.2 ml/min) during HE conditions to
compensate the volume loss [30]. Plasma samples were obtained
at 120, 0, 30, 50, 65, 80, 90, 100, 110, 120, 130, and 140 min. At
140 min, mice were anesthetized with Ketamine/Xylazine injection
(100 mg/kg and 12 mg/kg, respectively) and tissues were quickly
removed, immediately clamp-frozen in liquid nitrogen, and stored
at 80 C for following analysis.
2.3. siRNA preparation
2.3.1. Synthesis, puriﬁcation and formulation of liver-selective
mINDY-speciﬁc siRNA
RNA oligonucleotides were synthesized at a scale of 1 mmol (in vitro) or
10 mmol (in vivo) on a ABI 394 DNA/RNA or BioAutomation MerMade
12 synthesizer using commercially available 50-O-DMT-30-O-(2-
cyanoethyl-N,N-diisopropyl) phosphoramidite monomers (SAFC) of
uridine, 4-N-acetylcytidine (CAc), 6-N-benzoyladenosine (ABz) and 2-
N-isobutyrylguanosine (GiBu) with 20-O-TBDMS protection or 20-OMe
modiﬁcation and 50-O-DMT-thymidine-30-O-(2-cyanoethyl-N,N-diiso-
propyl) phosphoramidite (dT) following standard protocols for solid
phase synthesis and deprotection [31,32]. The crude oligonucleotides
were analyzed by anion-exchange high-performance liquid chroma-
tography (IEX) and LCeMS and puriﬁed by IEX using a linear gradient
of 10e50% buffer B in 30 min. Solutions of 0.02 M Na2HPO4 (pH11)
and 0.02 M Na2HPO4/1 M NaBr (pH11) were used as eluents A and B,
respectively. To ensure high ﬁdelity of the data, all single strands were
HPLC puriﬁed to >85% purity. The purity and identity of the oligo-
nucleotides was conﬁrmed by ion-exchange chromatography and LCe
MS, respectively. For the cell culture experiments, 100 mM stock so-
lutions were prepared by mixing equimolar amounts of complementary
sense and antisense strands in PBS buffer, heating the solution to
90 C for 10 min, and allowing it to slowly cool to room temperature to
complete the annealing process. siRNAs were further characterized by
HPLC and were stored frozen until use. Sequences of the modiﬁed
siRNA (siINDY) directed against murine mINDY mRNA and SCR are
depicted in Table 1. Formulation of siRNA for delivery to mouse liver
in vivo was done in lipid nanoparticles (LNPs) based on the Axolabs’
proprietary cationic lipid XL-10 (Axolabs, Kulmbach, Germany).
2.3.2. siRNA stability in mouse serum
Modiﬁed siRNAs were tested for nuclease stability in 50% mouse
serum. Therefore, 160 ml of 2.5 mM siRNA in 1 DPBS and 160 ml




50-CCA CAG AGU GCA CAA GUA A dTdT-30
SCR* 50-UUU CGC GUA UAC GCG AAA C dTdT-30
siINDY sense 50-CCA CAG AGU GCA CAA GUA A dTdT-30
siINDY antisense 50-UUA CUU GUG CAC UCU GUG G dTdT-30
SCR sense 50-AUC GUA CGU ACC GUC GUA U dTdT-30
SCR antisense 50-AUA CGA CGG UAC GUA CGA U dTdT-30
Capital letters: RNA; d:DNA.
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quenched with a stop solution (Lysis Solution, Proteinase K, water) at
65 C for 30 min. Prior to HPLC analysis on a Waters 2695 Separation
Module and a 2487 Dual Absorbance Detector, RNase-free water was
added to each sample. The solution was analyzed by HPLC using a
DNAPac PA200 analytical column (Thermo Scientiﬁc). Serum half-lives
were estimated for both strands of the siRNA and are shown in Table 2.
2.3.3. Immune stimulation of siRNA
Immuno-stimulative potential of siRNA was measured by secretion of
IFNa from freshly isolated and transfected human peripheral blood
mononuclear cells (PBMC). PBMCs were isolated from approx. 16 ml
blood of three healthy donors that was collected in Vacutainer tubes
coated with sodium heparin (BD, Heidelberg, Germany) according to
the manufacturer’s instructions. Subsequently, 100 nM siRNA was
reverse transfected into 100,000 PBMCs with 0.3 ml Lipofectamine
2000 per 96-well (n ¼ 2) in a total volume of 150 ml serum-free RPMI
medium for 24 h. Single-stranded RNA (“R-0006”) and DNA (“CpG
ODN”) oligonucleotides were applied as positive controls. 25 ml of the
supernatant was used for measurement of IFNa concentration using a
self-established electrochemiluminescence assay based on Meso-
Scale Discovery’s (MSD, Rockville, USA) technology. IFNa values are
shown in Table 2.
2.3.4. siRNA transfection
HEK293 cells stably expressing murine mINDY and carrying a FLAG-
tag for detection (HEK293-mINDY) were reversely transfected with
siRNAs using Lipofectamine RNAiMAX (Thermo Scientiﬁc) according to
the manufacturer’s instructions. To avoid variations in the transfection
efﬁciency when transfecting very low amounts for IC50 curves, 10 nM
of non-targeting control (SCR*) were used in each transfection mix. The
transfection was performed in 96-well plates adding 12,000 cells/well.
48 h post-transfection, RNA was isolated with the SV96 Total RNA
isolation system and gene expression was analyzed as described in
Richter et al., using primer for Slc13a5 (Mm01334459_m1, Thermo
Scientiﬁc) and RPL37a (Mm01546394_s1, Thermo Scientiﬁc) [33].
2.3.5. Cytotoxicity assay
Hepa1c1c7 mouse hepatoma cells were reversely transfected with
siRNAs using Lipofectamine RNAiMAX according to the manufacturer’s
instructions in 96-well plates. 72 h post-transfection, cell viability was
analyzed with the ViaLight Plus Cell Proliferation and Cytotoxicity
BioAssay Kit (Lonza, Cologne, Germany). Cytotoxicity was assessed in
relation to the non-transfected control cells, which were set 100%.
2.3.6. Citrate uptake assay
25,000 HEK293-mINDY were seeded overnight in 96-well Cytostar-T
scintillation plates (Perkin Elmer, Rodgau, Germany) or reversely





IC50KD (nM) 0.15 0.56
ImaxKD (%) 92 92
Serum stability (h): t1/2 in 50% mouse serum <2 4
Cytotoxicity (%): Viability of Hepa1c1c7 cells 78 135
Immune stimulation (pg/ml): IFNa release PBMCs 2144 70
ImaxKD: maximal knockdown of mINDY mRNA expression.
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and used 48 h post-transfection, washed, and incubated for 15 min in
the presence of 50 ml/well PBS containing 100 mM [1,5-14C]-citrate
(0.24 mCi/well; Perkin Elmer), 1% DMSO and the indicated concen-
trations of the compounds. Subsequently, cells were washed with ice-
cold PBS and cellular radioactivity was measured by liquid scintillation
counting. Four independent experiments carried out in technical
triplicates.
2.3.7. In-Cell Western Assay
HEK293-mINDY cells were reversely transfected in a 96-well format
with RNAiMAX as described in the section “siRNA transfection”.
48 h post-transfection, cells were ﬁxed with 3.7% formaldehyde
and the Odyssey In-Cell Western Assay (LiCor, Bad Homburg,
Germany) was performed according to the manufacturer’s in-
structions using an anti-FLAG M2 antibody (Sigma) overnight for
detection of FLAG-tagged mINDY. Subsequently, the plate was
incubated with a ﬂuorescently labeled secondary goat-anti-mouse
antibody (IRDye 800 CW, LiCor) and the CellTag 700 Stain (LiCor)
for normalization to cell number. Fluorescence was measured with
the Odyssey Scanner (LiCor).
2.4. Biochemical analysis
Plasma glucose levels of mice were determined by measuring at least
in duplicates (10% discrepancy) using Contour XT glucometer (Bayer
Vital, Leverkusen, Germany). Plasma NEFA were quantiﬁed by NEFA
HR(2) kit (Wako Chemicals, Neuss, Germany). Plasma insulin con-
centration was analyzed with Rat Insulin ELISA kit and mouse insulin
standard (Crystal Chem, Downers Grove, USA). Corticosterone levels
were measured in plasma samples using a competitive Corticosterone
ELISA kit (IBL International, Hamburg, Germany). Plasma lipid mea-
surements were performed with a Cobas 6000 c501 module (Roche/
Hitachi) according to manufacturer’s instructions. Liver lipids were
analyzed after lipid extraction described elsewhere [34,35], with an
AU680 Analyzer (Beckman Coulter/Olympus, Krefeld, Germany). As an
exception, phospholipids in serum and liver tissue were measured with
a Phospholipid kit from DiaSys (Holzheim, Germany). Inﬂammation
markers were analyzed in plasma samples of mice fasted for 16 h by a
Milliplex Assay with the MCYTOMAG-70k-PMX Mouse Cytokine/Che-
mokine Magnetic Bead Panel (Merck Millipore) for detection of TNFa,
IL-1b and IL-6.
2.5. Histochemistry
Liver slices were snap-frozen, embedded in Tissue-Tek (O.C.T.
Compound, Sakura, Staufen, Germany) on dry ice, and 5 mm cry-
osections were prepared for oil red O (ORO) and H&E staining. ORO
staining was carried out with 5 min incubation as described [36]. For
H&E sections were stained with Mayer’s Hemalaun for 15 min, 5 min
blued, dipped 5 in activated Eosin-G-solution, drained in an
ascending ethanol series, and mounted with Roti(R)-Histokitt II. 3
sections per liver as technical replicates were analyzed in bright ﬁeld
with 20 magniﬁcation on a BZ-9000 microscope (Keyence, Neu-
Isenburg, Germany), and images were quantiﬁed using ImageJ [37]
according to nature protocols [36]. Representative images are depic-
ted, scale (black bar) reﬂects 50 mm.
2.6. mRNA isolation and quantitative real-time PCR
Total RNA was extracted from snap-frozen tissue samples using TRIzol
reagent according to the manufacturer’s protocol. 1 mg RNA was
digested DNase and transcribed into cDNA via RevertAid Reverse
Transcriptase. Quantitative real-time PCR was performed on an ABI
7300 Real-Time PCR System with Maxima SYBR Green/ROX qPCRMOLECULAR METABOLISM 5 (2016) 1072e1082  2016TheAuthors. Published by ElsevierGmbH. This is an o
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expression. Primer sequences: Gapdh (forward CGTCCCGTAGA-
CAAAATGGT; reverse TGCCGTGAGTGGAGTCATAC) as well as Slc13a5
(mINDY: Mm_Slc13a5_va.1_SG), Slc13a2 (Mm_Slc13a2_1_SG),
Slc13a3 (Mm_Slc13a3_1_SG), Slc2a2 (Mm_Slc2a2_1_SG) and
Slc25a1 (Mm_Slc25a1_1_SG) as QuantiTect Primer Assay (Qiagen,
Hilden, Germany).
2.7. Data and statistical analyses
All data are presented as mean  SEM. GraphPad Prism 6 (La Jolla,
USA) was used to calculate statistics and draw graphs. SCR is depicted
as open bar/circle and siINDY as black bar/square. The homeostatic
model assessment of IR (HOMA-IR) was calculated using [HOMA-
IR ¼ (glucose * insulin)/405] after 16 h fasting [38]. Statistical dif-
ferences were calculated using one-tailed or two-tailed unpaired
Student’s t-test with Welch’s correction or ManneWhitney test
depending on whether data passed normal distribution tests and two-
way (repeated measurement) ANOVA adjusted for multiple testing and
Bonferroni’s multiple comparisons test for post hoc analysis where
appropriate. p < 0.05 was considered signiﬁcant.
3. RESULTS
3.1. Structure, modiﬁcation and evaluation of a liver-selective
mINDY-speciﬁc siRNA
A commercially available siRNA (siINDY*) against murine Slc13a5
(mammalian INDY homolog, mINDY) inhibited the mINDY mRNA and
reduced citrate uptake in HEK293 stably transfected with murine
mINDY. In order to improve its pharmacokinetics, the siRNA was
modiﬁed by introducing 20-O-methylgroups and phosphorothioate.
Several different derivatives were analyzed and the siRNA with the best
proﬁle was chosen for chronic administration. This modiﬁed siRNA
(siINDY) showed improved serum stability and a strongly reduced
immune stimulatory potential in relation to the unmodiﬁed siRNA
(Table 2). siINDY also revealed a considerable ability to suppress
mINDY expression to background (Figure 1A). The protein levels of
mINDY in stably transfected HEK293-mINDY cells and citrate uptake
were signiﬁcantly reduced with 1 and 10 nM of siRNA (Figure 1B,C,
respectively). To provide a liver-speciﬁc delivery, siRNAs were
formulated with lipid nanoparticles targeting the oligonucleotides to
hepatocytes.
3.2. Knockdown of mINDY expression in vivo
In a ﬁrst pilot test in mice, siINDY showed an effective down-regulation
of mINDY mRNA in liver 6 days after injection, whereas a non-silencing
scrambled control siRNA (SCR) and another off-target-speciﬁc, mINDY-
unrelated siRNA revealed no mINDY knockdown at any time-point
(Figure 1D). We next treated C57BL/6J mice with siINDY or SCR
siRNA to elucidate the metabolic effects of liver-selective mINDY mRNA
down-regulation in vivo. The highest expression of mINDY was
detectable in liver and kidney, with very low levels of transcripts in
skeletal muscle (SKM). After 8 weeks of siRNA treatment siINDY
reduced the mINDY expression in liver by more than 60%, whereas
mINDY expression in kidney and SKM were unaffected (Figure 1E).
Notably, mRNA expression of other solute carrier family members as
Slc13a2 (Naþ-sulfate/carboxylate cotransporter) and Slc13a3 (so-
dium-dependent dicarboxylate transporter), both with conserved
structural homologies to INDY, Slc2a2 (GLUT-2), and Slc25a1 (mito-
chondrial citrate transporter) showed no reduction in liver under INDY-
speciﬁc siRNA treatment compared to SCR endorsing the mINDY
speciﬁcity of the siRNA (Figure 2B).pen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1075
Figure 1: In vitro (AeC) and in vivo (D and E) validation of mINDY-speciﬁc siRNA (siINDY). (A) Doseeresponse curves upon transfection of HEK293 cells stably over-
expressing mINDY carrying a FLAG-tag (HEK293-mINDY) with siINDY and its unmodiﬁed form (siINDY*) (n ¼ 2). (B) Transfection of HEK293-mINDY with siINDY reduced mINDY
protein in a concentration-dependent manner, determined by anti-FLAG In-Cell Western Assay (n ¼ 3). The black arrow indicates background ﬂuorescence signal of HEK293 wild-
type cells analyzed in parallel. (C) Transfection of HEK293-mINDY cells with siINDY reduced cellular citrate uptake (n ¼ 3). (D) Pilot mouse study to evaluate the siRNA efﬁcacy.
mINDY mRNA expression in liver 2 and 6 days after injection normalized to GAPDH and control siRNA at day 2 (n ¼ 3). (E) mINDY mRNA expression in liver, kidney, and muscle
tissue after 8 weeks of siRNA treatment normalized to GAPDH and control siRNA in liver (n ¼ 4). Data are represented as mean  SEM. Two-way ANOVA with Bonferroni’s multiple
comparisons test. Scrambled control siRNA (SCR): open bars; off-target-speciﬁc mINDY-unrelated siRNA (OT): fasciated bars; mINDY-speciﬁc unmodiﬁed siRNA (siINDY*): grey
triangle; mINDY-speciﬁc modiﬁed siRNA (siINDY): black bars.
Original ArticleTo investigate the effects of mINDY down-regulation on body
composition and metabolic parameters, 8 week-old C57BL6/J mice
were grouped according to fat mass (Figure 2C). Due to grouping by
equal fat mass the body weight was slightly lower in the siINDY group
compared to SCR with 24.6 g and 26.0 g, respectively (Supplemental
Table A2). In both groups, siRNAs were injected weekly via tail vein in a
body weight-matched fashion, and the siRNA intervention was com-
bined with feeding a WD ad libitum. To assess dietary effects, body
composition was measured by 1H-nuclear magnetic resonance, before
the intervention, in week 5 and in week 7 before catheter implantation
for the HE clamp. During intervention, fat content, free ﬂuids, and lean
mass showed similar progression (Figure 2CeE). No beneﬁcial effect
on whole-body fat accumulation was detected. Mice similarly
increased their body weight over the study period (Figure 2F). This gain
in body weight was predominantly a consequence of an increasing fat
mass. For further characterization a metabolic cage study was per-
formed in week 5. Here, both groups fed similar amounts of HFD1076 MOLECULAR METABOLISM 5 (2016) 1072e1082  2016The Authors. Published by Elsevier GmbH.during light and dark phase (Figure 3A, left). However, liquid intake in
dark phase was reduced in mice treated with siINDY (Figure 3A, right).
Hence, the total daily liquid consumption was also signiﬁcantly
reduced in the siINDY group (4.9 0.4 and 3.8 0.3 ml/kg/h for SCR
and siINDY, respectively, p ¼ 0.025). However, the total caloric intake
combined from HFD and the 6% sucrose in the water was similar in
both groups (Supplemental Table A2). The locomotor activity was low
during daytime and increased rapidly with onset of the night phase, yet
without any statistical differences (Figure 3B). Analysis of O2-con-
sumption, CO2-production, and energy expenditure (EE) adjusted on
lean mass also revealed no differences (Figure 3C and Supplemental
Table A2). Likewise, no evidence was found for a change of the res-
piratory exchange ratio (RER) during light and dark phase within
treatments (Figure 3D).
In summary, liver-selective mINDY knockdown did not prevent WD-
induced changes of body composition or body weight within the 8
week intervention.This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Liver-selective mINDY-speciﬁc siRNA approach. (A) Schematic of the mouse experiment. (B) mRNA expression of indicated genes in liver of clamped mice
normalized to GAPDH (n ¼ 7, two-tailed Student’s t-test with Welch’s correction). (CeE) Body composition measurement for fat mass (C), free ﬂuids (D), and lean mass (E) at start
(0 wk), after 5 weeks (5 wk) and before catheterization (7 wk) (n ¼ 16). (F) Weight gain during intervention (n ¼ 16). Data represent mean  SEM. Black arrows: Recording of body
weight/siRNA injection, Grey arrows: Procedures: BC: Body composition, MCA: Metabolic cage analysis, OP: Catheterization.3.3. Metabolic characterization of mINDY knockdown
Changes in metabolic parameters were reported for the whole-body
mINDY KO [16]. Basal metabolic parameters were analyzed in
plasma of fasted mice. We found no differences of non-esteriﬁed free
fatty acids (NEFA), blood glucose, and insulin levels between treatment
groups (Supplemental Table A2).MOLECULAR METABOLISM 5 (2016) 1072e1082  2016TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.comTo assess the effect of mINDY knockdown on glucose homeostasis in
week 5, an ipGTT was conducted in mice fasted for 16 h. Both groups
showed similar blood glucose levels during the ipGTT (Figure 3E). No
effect of mINDY knockdown on glucose tolerance was observed,
neither evaluating the ipGTT by analysis of AUC (data not shown). Thepen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1077
Figure 3: Metabolic characterization of siRNA-treated mice during metabolic cage analysis (AeD, n ¼ 10) and ipGTT (EeF). (A) Food intake (left) and liquid consumption
(with 6% sucrose, right) during light- and dark-phase (repeated measurement ANOVA with Bonferroni’s multiple comparisons test). (B) Locomotor activity. (C) Energy expenditure.
(D) Respiratory exchange ratio (VCO2/VO2). (E) Plasma glucose during ipGTT (n ¼ 16). (H) According insulin levels during ipGTT (n ¼ 15). Data represent mean  SEM. Grey
background indicates dark-phase.
Original Articlecorresponding insulin levels revealed no signiﬁcant differences during
the ipGTT (Figure 3F).
Thus, the mINDY-speciﬁc siRNA treatment revealed no major changes
of basal metabolic parameters.
3.4. mINDY knockdown increased insulin-induced suppression of
endogenous glucose production
The whole-body mINDY KO revealed a protective effect from HFD-
induced IR [16]. Therefore, the effect of mINDY knockdown on the
peripheral and hepatic insulin sensitivity was investigated by HE
clamps in restrained, conscious mice with radioactive tracers at 8
weeks of intervention. At the HE clamp day, fasted siINDY-treated mice
were slightly lighter than the SCR group but showed similar basal
fasting glucose levels and a comparable HOMA-IR (Supplemental
Table A3). Mice were clamped at 120 mg/dl blood glucose and held
constant in the steady state phase of the HE clamp (Figure 4A and
Supplemental Table A3). Although the glucose infusion rate (GIR) for1078 MOLECULAR METABOLISM 5 (2016) 1072e1082  2016The Authors. Published by Elsevier GmbH.siINDY was elevated during the steady state, that difference was not
signiﬁcant (Figure 4A). Due to the insulin stimulation under hyper-
insulinemic conditions plasma NEFA were reduced in both groups
(Figure 4B). siINDY mice exhibited a 50% reduction and SCR mice
exhibited a 29% reduction, again without a statistical difference. This
might indicate a moderately improved insulin sensitivity induced by
suppression of lipolysis within siINDY mice. To evaluate the impact of
mINDY knockdown on hepatic insulin sensitivity, the endogenous
glucose production (EGP) was determined. Under basal conditions the
EGP of fasted mice was comparable (Figure 4C, left, 19.0  5.0 vs.
16.7  1.4 mg/kg/min for SCR and siINDY, respectively). However,
during the HE clamp the siINDY group showed virtually no EGP, while
the insulin suppression within the SCR group was about 50% of the
basal EGP (Figure 4C, right, 8.29  2.47 vs. 0.36  1.84 mg/kg/min
for SCR and siINDY, respectively) Thus, the EGP was almost completely
inhibited in the steady state in siINDY-treated mice reﬂecting a pre-
served insulin sensitivity of EGP (Figure 4D, 52.3 vs. 96.1% for SCRThis is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Improvement of insulin sensitivity with mINDY-speciﬁc siRNA during HE clamp. (A) Blood glucose (top) at basal and insulin-stimulated phase and according
glucose infusion rate (GIR, bottom) to maintain plasma glucose at 120 mg/dl. (B) Insulin-mediated reduction of plasma NEFA. (C) Endogenous glucose production (EGP). (D).
Suppression of EGP. (E) Whole-body glucose uptake during steady state. (F) 2-DG uptake of SKM (Gastrocnemius) and epididymal WAT. Data represent mean  SEM. n ¼ 7. Two-
tailed Student’s t-test with Welch’s correction.and siINDY, respectively). The peripheral insulin action was evaluated
by the whole-body glucose uptake and the tissue-speciﬁc 2-Deoxy-D-
glucose (2-DG) uptake. The whole-body glucose uptake during insulin-
stimulation showed no difference between treatment groups
(Figure 4E). Rates of glucose clearance at basal level and under clamp
conditions, glycolysis, glycogen synthesis and corticosterone levels in
the steady state revealed no differences (Supplemental Table A3).
Insulin-stimulated 2-DG uptake in peripheral organs revealed no
impact of mINDY knockdown in SKM (Gastrocnemius) and epididymal
white adipose tissue (WAT) (Figure 4F).
In summary, siINDY-treated mice showed an improved hepatic insulin
sensitivity with an improved insulin-suppression of EGP, while the
whole-body insulin sensitivity was not substantially changed.
3.5. mINDY knockdown lowered liver lipids
Recently, Li and colleagues observed that mINDY knockdown was
sufﬁcient to repress lipid formation in HepG2 cells [24]. To addressMOLECULAR METABOLISM 5 (2016) 1072e1082  2016TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.comwhether the siINDY treatment also affected hepatic lipid storage,
overnight fasted, non-catheterized mice were sacriﬁced and organ
weights were determined. Livers of the siINDY group showed a 10%
reduced weight (Figure 5A, 1133  34 vs. 1035  33 mg SCR and
siINDY, respectively, p ¼ 0.04). Other analyzed organs and fat depots
(epididymal (e), perirenal (p), subcutaneous (s) WAT) displayed similar
weights between groups. To monitor liver morphology, H&E stainings
were performed. Liver tissues of both groups showed no obvious
pathological morbidities (Figure 5B) although more lipids droplets were
visible in liver tissue of the SCR group. To evaluate the lipid content in
liver, oil red O (ORO) stainings were conducted. Less and smaller lipids
droplets were found in liver sections of siINDY mice (Figure 5C).
Densitometric quantiﬁcation of neutral lipids stained by ORO demon-
strated a reduced lipid content in liver sections of siINDY-treated mice
(Figure 5D). Metabolic parameters (triglycerides, cholesterol, HDL,
LDL, and phospholipids) and different inﬂammation markers were
analyzed in plasma without revealing any difference (Supplementalpen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1079
Figure 5: mINDY-speciﬁc siRNA decreased hepatic lipid content. (A) Weight of indicated organs and epididymal (e), perirenal (p), and subcutaneous (s) WAT after 16 h fasting.
(B) Representative H&E staining of liver. (C) Representative ORO staining. (D) Quantiﬁcation of ORO stainings by densitometric analysis. (E) Triglyceride content in liver lysates. Data
represent mean  SEM. n ¼ 4. One-tailed Student’s t-test with Welch’s correction. Black scales indicate 50 mm.
Original ArticleTable A4). In liver lysates cholesterol content and phospholipids were
also unchanged (Supplemental Table A4), while siINDY mice showed
reduced triglyceride levels in liver homogenates (Figure 5E).
Taken together, we demonstrate that the pharmacological knockdown
of mINDY by RNAi in vivo improved hepatic insulin sensitivity and
effectively prevented lipid accumulation, especially triglycerides in
liver. Hence, mINDY inhibition is able to counteract diet-induced fatty
liver disease (FLD).
4. DISCUSSION
Our data show that inhibition of mINDY exclusively in the liver is able to
reduce hepatic lipid accumulation and improve hepatic insulin sensi-
tivity. We revealed that our modiﬁed liver-selective a mINDY-speciﬁc
siRNA could prevented a diet-induced steatosis in mice. Moreover,
we observed an improved insulin sensitivity by mINDY knockdown.
FLD is a world-wide healthy concern. Our data provide novel mech-
anistic insights into the understanding of mINDY action but also
describe that mINDY inhibition is a feasible potential therapeutic option
to prevent FLD.
Our ﬁndings partially support previous results but also add consider-
able novel aspects to our understanding of mINDY function. Along
these lines, mINDY KO mice were protected from HFD-induced obesity,
IR and FLD [16]. However, the contribution of single organs and tissues
is difﬁcult to discern in constitutive whole-body KO animals. Our data
reveal that the effect of mINDY on liver fat and insulin sensitivity can be
dissociated from an effect on adiposity. Speciﬁcally, our siRNA-based1080 MOLECULAR METABOLISM 5 (2016) 1072e1082  2016The Authors. Published by Elsevier GmbH.experiments show improved hepatic insulin sensitivity and prevention
of FLD, although body weight is unchanged in the treated animals.
Thus, a liver-speciﬁc phenotype does not require changes of whole-
body fat or body weight. Recent data from another study using RNAi
in rats to inhibit mINDY showed similar results [39]. However, that
study did not demonstrate speciﬁcity or liver-selectivity of the inves-
tigated siRNA. Therefore, it remained unclear, which effects can be
observed by liver-speciﬁc knockdown. Additionally, the authors did not
provide further data on the inhibition. We evaluated our modiﬁed siRNA
in vitro (Figure 1AeC) and tested the efﬁcacy, speciﬁcity, and liver-
selectivity by screening mINDY expression in liver, kidney, and mus-
cle as well as the hepatic expression of other family members
(Figure 1D,E and 2B).
Considering the results of the KO and the fact that mINDY is pre-
dominantly expressed in liver, we found the lack of any difference in
body weight somewhat surprising and speculated that eventually our
experiment was too short to induce changes of body weight. We
suggest that conditional KO experiments should investigate the role of
e.g. neuron-speciﬁc mINDY expression in the brain on energy ho-
meostasis. It should also be noted that the knockdown resulted in
approximately 35% remaining mINDY activity and that we here
investigated an acute inhibition of mINDY while the genetic KO has a
complete deletion of mINDY activity over the whole period of life,
including prenatal development, which may also explain differences
between the genetic KO model and the here observed ﬁndings.
For the siRNA-treated mice we assessed the insulin sensitivity using
the HE clamp. Comparable to the KO experiments, we observedThis is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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improved hepatic insulin sensitivity with a strongly reduced EGP even
though the knockdown efﬁciency was not 100% such as with the
mINDY KO. We showed that none of the other presumably relevant
transporters compensated for mINDY knockdown or was targeted by
the liver-selective mINDY-speciﬁc siRNA (Figure 1B). The siRNA
appeared to affect also whole-body insulin sensitivity, although these
effects were not signiﬁcant. Mice exhibited a higher GIR during the HE
clamp and a more substantial reduction of NEFA in reaction to
hyperinsulinemia during the HE clamp. Speciﬁc 2-DG uptake into
peripheral tissues (SKM and WAT) was not affected by mINDY inhi-
bition during the HE clamp (Figure 4F). Notably, the KO showed a
signiﬁcantly increased glucose uptake into SKM during a HE clamp
[16]. Theoretically, our study may have been underpowered to detect
small differences in peripheral insulin sensitivity. However, it should be
noted that the siRNA did not target SKM, which most likely explains the
lacking effect on glucose uptake into SKM (Figure 1E). Our experi-
mental setting did not include overt diabetic models. Although effects
on glucose metabolism in our study were moderate, those overt dia-
betic models should be investigated in future experiments to evaluate
the potential of mINDY inhibition in terms of diabetes treatment.
In general, our ﬁnding of reduced liver fat accumulation under mINDY
inhibition is in line with previous results demonstrating that mINDY is
relevant for triglyceride metabolism. Decreased activity of mINDY (or its
orthologs) in D. melanogaster and C. elegans increased longevity
similarly to caloric restriction and was associated with reduced lipid
accumulation in those organisms [11,20e22,40,41]. mINDY deletion in
mice decreased HFD-induced adiposity, lipid accumulation into liver and
SKM, and improved insulin sensitivity without affecting caloric intake
[16]. In addition to those data, we now show that mINDY inhibition has a
considerable therapeutic potential and that effects on local lipid accu-
mulation are unlikely to depend on changes in the degree of adiposity.
Some limitations of our study should be mentioned. Our approach has
a considerable risk of off-target effects. Although we aimed to
establish a rather speciﬁc approach, some of those effects are likely to
exist. Array data from control and siINDY-treated mice did not show
any altered regulation or off-target effects (data not shown). Thus, the
ﬁndings described here are likely to result from mINDY inhibition rather
than non-speciﬁc effects.
Although we demonstrated that our siRNA inhibited mINDY predomi-
nantly in the liver and did not affect expression in adipose tissue, skeletal
muscle, or kidney, we cannot entirely exclude that other organs may
have been affected such as central nervous system. Considering our
modiﬁcations, the siRNA should not have crossed the bloodebrain-
barrier. However, this has not been analyzed directly and future ex-
periments on the role of mINDY in the brain are desirable. HFD in C57BL/
6 mice usually does not induce substantial hepatitis within the given
time period [42]. Nevertheless mINDY and HFD may modify inﬁltration of
speciﬁc immune cells. Due to the radioactive state of the material after
clamp, a detailed immune cell phenotyping of the liver was not per-
formed within our study and would be desirable in future studies.
Our ﬁndings suggest that mINDY inhibition is a reasonable therapeutic
option to prevent FLD. However, our data are restricted to rodents, and
it is unclear whether comparable effects can be observed in humans.
Despite this uncertainty, notably comparable ﬁndings on lipid accu-
mulation were observed in C. elegans and D. melanogaster [21,22].
Therefore, the relevance of mINDY appears to be a conserved mech-
anism, and we believe that further experiments including early human
studies are warranted to further investigate the potential of this ther-
apeutic approach.
In conclusion, our data demonstrate that mINDY is involved in
regulation of liver fat metabolism. Its inhibition by a liver-speciﬁcMOLECULAR METABOLISM 5 (2016) 1072e1082  2016TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.comsiRNA is a reasonable approach to prevent FLD in C57BL/6J mice
on WD; however, it had no effect on body weight. Our data support
that effects on hepatic lipid accumulation occur independent of
body weight changes or whole-body fat content. We suggest that
non-liver mINDY effects, such as brain activity, may mediate po-
tential effects on body weight. Future experiments addressing the
relevance of central-nervous mINDY activity and investigating the
therapeutic effects on glucose metabolism in overt diabetic models
are desirable.
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